A Phase II Study of Paclitaxel and Carboplatin with a Biweekly Schedule in Patients with Epithelial Ovarian Cancer: Gynecologic Cancer Network Trial
| Autor: | Daisuke Doi, Kenichi Tanaka, Takashi Matsushima, Hiroki Nakayama, Kazuyuki Fujita, Koichi Yoneyama, Toshiyuki Takeshita, Hisamori Kato, Shigeru Honma, Seiryu Kamoi, Hirobumi Asakura, Yoichi Aoki, Tetsuro Yahata, Hideki Konishi, Shoji Kodama |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Paclitaxel Nausea medicine.medical_treatment Phases of clinical research Antineoplastic Agents Carcinoma Ovarian Epithelial Neutropenia Drug Administration Schedule Carboplatin chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasms Glandular and Epithelial Aged Aged 80 and over Ovarian Neoplasms Chemotherapy business.industry Combination chemotherapy General Medicine Middle Aged medicine.disease Antineoplastic Agents Phytogenic Chemotherapy regimen Treatment Outcome chemistry Female medicine.symptom business Ovarian cancer |
| Zdroj: | Journal of Nippon Medical School. 81:28-34 |
| ISSN: | 1347-3409 1345-4676 |
| Popis: | AIM The objective of this multicenter phase II study was to evaluate the effects of biweekly paclitaxel and carboplatin combination chemotherapy on response rate and toxicities in patients with epithelial ovarian cancer. PATIENTS AND METHODS Patients with International Federation of Gynecology and Obstetrics stage II to IV ovarian cancer received paclitaxel at a dose of 120 mg/m(2) and carboplatin at an area under the curve of 3 mg/mL per minute every 2 weeks for 8 or more cycles. Inclusion criteria included an Eastern Cooperative Oncology Group performance status of 0 to 2 and no previous chemotherapy. Informed consent was obtained from each patient before the start of treatment. RESULTS From March 2003 through July 2009, 42 patients from 5 institutions were eligible to be evaluated for response and toxicity. The median age was 60.5 years (age range, 34-81 years). The International Federation of Gynecology and Obstetrics stage was stage II in 3 patients, stage III in 31 patients, and stage IV in 8 patients. The response rate was 66.7% (95% confidence interval: 50.5%-80.4%). Sixty-nine percent (29 of 42) of patients received 8 or more cycles of chemotherapy. The median progression-free survival was 18.5 months, and overall survival was 59.1 months. The most common grade 3 or 4 hematological toxicity was neutropenia (61.0%). No patients had grade 3 or 4 thrombocytopenia. The most common grade 3 nonhematological toxicities were neuropathy (4.9%) and nausea (2.4%). CONCLUSION Paclitaxel combined with carboplatin using a biweekly schedule is a safe and effective chemotherapy regimen for patients with epithelial ovarian cancer. Our results suggest that a biweekly schedule is well tolerated and is less toxic than a triweekly schedule. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|